Antengene Starts Pivotal Phase III Study of ATG-022 for Cancer Treatment

Antengene Commences Phase III Trial for ATG-022 in Cancer Treatments

Antengene Corporation Limited, a noted global biotechnology enterprise, has recently announced that the first patient has been enrolled in the crucial Phase III CLINCH-3 clinical trial of its drug ATG-022 in China. This innovative compound, which is an antibody-drug conjugate targeting CLDN18.2, is currently being evaluated for its efficacy in treating patients diagnosed with advanced gastric or gastroesophageal junction adenocarcinoma.

ATG-022 has previously earned the Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE)—a move that has streamlined communication with regulatory bodies and expedited the trial’s advancement. The CLINCH-3 study was initiated following promising results from prior Phase I/II trials, which indicated that ATG-022, when used alone, exhibited a robust efficacy and a favorable safety profile in patients with advanced gastric cancer.

Background of the Trial

The Phase III study is led by Professor Lin Shen from Peking University Cancer Hospital, serving as the principal investigator. It is structured as a randomized, controlled, open-label study across multiple centers. Patients enrolled will receive either ATG-022 or the treatment determined by their attending physician. The goal is to confirm the drug’s efficacy and safety compared to current treatment options.

The prior studies, particularly the Phase I/II CLINCH studies, revealed promising outcomes. Among patients with moderate to high CLDN18.2 expression, the overall response rate (ORR) in one of the tested cohorts was approximately 46.7%, indicating that nearly half of the patients responded favorably to treatment. Furthermore, the disease control rate (DCR) reached 86.7%, showcasing robust therapeutic activity.

The findings also highlighted that ATG-022 was generally well tolerated. Except for a slight increase in adverse events related to treatment as observed in the latest follow-up, the incidence of serious side effects remained stable across the cohort, suggesting a manageable safety profile. These characteristics bolster the potential of ATG-022 to be recognized as a leading treatment option for patients with this challenging type of cancer.

Clinical Implications

Professor Lin Shen expressed optimism regarding the significance of this trial for patients who struggle with advanced gastric cancer, which often has poor prognosis despite existing therapies. The potential of ATG-022 to meet an urgent medical need is underscored by the shortcomings faced by patients after progressing through traditional treatment avenues.

In addition to CLINCH-3, Antengene has ambitious plans for ATG-022, including CLINCH-2, which will assess its application in combination with standard chemotherapy and anti-PD-1 therapies to maximize the therapeutic window. There is also a basket trial underway to evaluate ATG-022’s performance in various non-gastric tumors expressing CLDN18.2.

The Future of Antengene

Armed with the momentum of these developments, Antengene aims to broaden the breadth of ATG-022's therapeutic indications. With the registration process in mind, the company is not just focused on enhancing treatment for gastric cancer but is also expanding research to address other solid tumors that share similar biological markers.

In summary, the commencement of the CLINCH-3 study signifies a pivotal moment for Antengene as it strives toward innovation in cancer treatment. The close collaboration between researchers, institutions, and the biotechnology leader itself will be crucial in navigating this next phase of clinical development.

Antengene remains dedicated to delivering quality healthcare solutions across the globe, backed by a robust portfolio of investigational drugs including ATG-022 and others that are tailored to meet high medical needs. As they forge ahead in this clinical landscape, outcomes from the CLINCH-3 study will undoubtedly provide key insights into enhancing patient health outcomes in oncology treatments.